EGFR and non-small cell lung carcinoma: In recent years, epidermal growth factor receptor (EGFR) inhibitor development and application has shown significant benefits for advanced or metastatic EGFR-positive NSCLC patients, [4–8] though progress is generally evident after about 9 to 13 months of treatment.